Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Roberto Cilia, Albert Akpalu, Fred Stephen Sarfo, et al.
Brain (2014) Vol. 137, Iss. 10, pp. 2731-2742
Open Access | Times Cited: 288

Showing 1-25 of 288 citing articles:

Parkinson's disease
Bastiaan R. Bloem, Michael S. Okun, Christine Klein
The Lancet (2021) Vol. 397, Iss. 10291, pp. 2284-2303
Open Access | Times Cited: 2117
Diagnosis and Treatment of Parkinson Disease
Melissa J. Armstrong, Michael S. Okun
JAMA (2020) Vol. 323, Iss. 6, pp. 548-548
Closed Access | Times Cited: 2070
Parkinson’s Disease
Stephen G. Reich, Joseph M. Savitt
Medical Clinics of North America (2018) Vol. 103, Iss. 2, pp. 337-350
Closed Access | Times Cited: 393
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Wolfgang H. Oertel, Jörg B. Schulz
Journal of Neurochemistry (2016) Vol. 139, Iss. S1, pp. 325-337
Open Access | Times Cited: 313
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
Peter A. LeWitt
Movement Disorders (2014) Vol. 30, Iss. 1, pp. 64-72
Closed Access | Times Cited: 305
Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
Francesca Magrinelli, Alessandro Picelli, Pierluigi Tocco, et al.
Parkinson s Disease (2016) Vol. 2016, pp. 1-18
Open Access | Times Cited: 300
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Alberto J. Espay, Francesca Morgante, Aristide Merola, et al.
Annals of Neurology (2018) Vol. 84, Iss. 6, pp. 797-811
Open Access | Times Cited: 282
Clinical spectrum of levodopa‐induced complications
Camila C. Aquino, Susan H. Fox
Movement Disorders (2014) Vol. 30, Iss. 1, pp. 80-89
Closed Access | Times Cited: 240
Dopamine, Oxidative Stress and Protein–Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases
Enrico Monzani, Stefania Nicolis, Simone Dell’Acqua, et al.
Angewandte Chemie International Edition (2018) Vol. 58, Iss. 20, pp. 6512-6527
Closed Access | Times Cited: 215
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
M. Angela Cenci
Frontiers in Neurology (2014) Vol. 5
Open Access | Times Cited: 202
The role of dopamine in the brain - lessons learned from Parkinson's disease
David Meder, Damian M. Herz, James B. Rowe, et al.
NeuroImage (2018) Vol. 190, pp. 79-93
Open Access | Times Cited: 169
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
Rob M.A. de Bie, Carl E Clarke, Alberto J. Espay, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 452-461
Closed Access | Times Cited: 157
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Destany K. Kwon, Mohit Kwatra, Jing Wang, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3736-3736
Open Access | Times Cited: 78
The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations
Raúl Martínez‐Fernández, Emmanuelle Schmitt, Pablo Martínez‐Martín, et al.
Movement Disorders (2016) Vol. 31, Iss. 8, pp. 1080-1094
Closed Access | Times Cited: 138
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Roberto Cilia, Emanuele Cereda, Albert Akpalu, et al.
Brain (2020) Vol. 143, Iss. 8, pp. 2490-2501
Open Access | Times Cited: 122
Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical management
Sanjay Pandey, Prachaya Srivanitchapoom
Annals of Indian Academy of Neurology (2017) Vol. 20, Iss. 3, pp. 190-190
Open Access | Times Cited: 117
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
Tai Ngoc Tran, Trang N. N. Vo, Karen Frei, et al.
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1109-1117
Closed Access | Times Cited: 117
Ethnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review
Aaron Ben-Joseph, Charles R. Marshall, Andrew J. Lees, et al.
Journal of Parkinson s Disease (2019) Vol. 10, Iss. 1, pp. 31-45
Open Access | Times Cited: 107
Risk and course of motor complications in a population-based incident Parkinson's disease cohort
Anders Bjørnestad, Elin Bjelland Forsaa, Kenn Freddy Pedersen, et al.
Parkinsonism & Related Disorders (2015) Vol. 22, pp. 48-53
Closed Access | Times Cited: 101
Young-onset Parkinson's disease: Its unique features and their impact on quality of life
Raja Mehanna, Joseph Jankovic
Parkinsonism & Related Disorders (2019) Vol. 65, pp. 39-48
Closed Access | Times Cited: 101
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
Daphne Robakis, Stanley Fahn
CNS Drugs (2015) Vol. 29, Iss. 6, pp. 433-441
Open Access | Times Cited: 98
Mucuna pruriens in Parkinson disease
Roberto Cilia, Janeth Laguna, Erica Cassani, et al.
Neurology (2017) Vol. 89, Iss. 5, pp. 432-438
Open Access | Times Cited: 92
Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
Muthuraman Muthuraman, Nabin Koirala, Dumitru Ciolac, et al.
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 92
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
Jie Dong, Yanhua Cui, Song Li, et al.
Current Neuropharmacology (2016) Vol. 14, Iss. 4, pp. 339-355
Open Access | Times Cited: 89
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
Takuya Uehara, Chi‐Jing Choong, Masayuki Nakamori, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 87
Page 1 - Next Page

Scroll to top